Close Menu

This article has been updated with additional information from Roche's earnings call.

NEW YORK (GenomeWeb) – Roche today reported an 8 percent year-over-year increase in revenues for its Diagnostics division for the first half of 2018, driven primarily by demand for immunodiagnostic solutions, which are part of the Centralized and Point of Care Solutions business segment.

For the first half of the year, the Roche Group reported CHF 28.11 billion ($28.34 billion) in total sales, up 7 percent from CHF 26.34 billion during the first half of 2017.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.

A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.

NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.

In Nature this week: epigenetic factors that prevent healthy aging and more.

Mar
18
Sponsored by
Roche

This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.